Epizyme, Inc. Soared
Mon, Jun 27, 2022 at 08:30 PM

Epizyme, Inc. (EPZM:NASDAQ) shot up at $1.48, representing a gain of 55.1%. On Mon, Jun 27, 2022, EPZM:NASDAQ touched a New 2-Week High of $1.48. The stock appeared on our News Catalysts scanner on Mon, Jun 27, 2022 at 06:32 PM in the 'ACQUISITION' category. From Mon, Jun 13, 2022, the stock recorded 66.67% Up Days and 60.00% Green Days
About Epizyme, Inc. (EPZM:NASDAQ)
Epizyme Inc is a clinical stage biopharmaceutical company. The Company discovers, develops and commercializes novel epigenetic therapies for cancer patients.
Top 10 Gainers:
- Evofem Biosciences, Inc. (EVFM:NASDAQ), 187.71%
- Acutus Medical Inc. (AFIB:NASDAQ), 87.59%
- Epizyme, Inc. (EPZM:NASDAQ), 55.14%
- Axsome Therapeutics, Inc. (AXSM:NASDAQ), 51.39%
- NeuroSense Therapeutics Ltd. (NRSN:NASDAQ), 48.81%
- Bellerophon Therapeutics, Inc. (BLPH:NASDAQ), 42.39%
- InflaRx N.V. (IFRX:NASDAQ), 38.28%
- Kiromic BioPharma Inc. (KRBP:NASDAQ), 36.14%
- Visionary Education Technology Holdings Group Inc. (VEDU:NASDAQ), 33.16%
- Aspira Women's Health Inc. (AWH:NASDAQ), 32.39%